Study wrapper · #740
Mitochondrial-derived microproteins in cancer and neurodegeneration: A new era of cross-disease mechanistic insights.
Editor's note
This review examines how mitochondrial-derived microproteins, humanin, MOTS-c, SHLPs, and the newer SHMOOSE, translate mitochondrial stress into cell-fate decisions across ageing, cancer, and neurodegeneration. MOTS-c is covered at the pathway level (AMPK/NRF2-LARS1/mTORC1), and the piece usefully frames context-dependence: the same peptides can be protective in neurons yet co-opted by tumours. As a synthesis it aggregates mechanism rather than testing outcomes, and it makes no clinical efficacy claims. For MOTS-c readers it offers a coherent map of signalling architecture and the intriguing cancer-versus-Alzheimer's inverse-comorbidity angle. Publishable as advanced landscape context, with the standing caveat that these are mechanistic and preclinical insights, not evidence of therapeutic benefit.
Plain-language abstract
Mitochondrial-derived microproteins (MDPs) are tiny proteins made from mitochondrial DNA that translate cellular stress into decisions about whether a cell survives, dies, or changes behaviour. This review looks at the main ones, humanin, MOTS-c, SHLPs, and a newly found one called SHMOOSE, and how they act in ageing, cancer, and brain diseases. A key theme is that the same peptide can help in one setting and harm in another: MDPs can protect nerve cells but may also be hijacked by tumours to survive and resist treatment, which the authors link to the curious observation that cancer and Alzheimer's disease tend not to occur together. For MOTS-c specifically, the review lays out the signalling pathways it uses. Because this is a summary of existing science rather than a new experiment, it does not prove any treatment benefit. For readers it gives a helpful, if advanced, overview of how MOTS-c and its relatives work and why their effects depend heavily on context.